Cellectis SA (CLLS)

Cellectis SA (CLLS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $135M; returns 1 day +0.5%, 1 week -5.8%, 1 year -71.8%.

Cellectis S.A. is a clinical-stage biotechnology company focused on developing off-the-shelf (allogeneic) CAR-T cell therapies for cancer. Their pioneering gene editing platform is used to create innovative therapies.

Groups CLLS belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Gene Therapy
• Healthcare
• Cancer Therapeutics
• Immunotherapy
• Clinical Stage
• Life Sciences
• R&D

CLLS financial model: income statement, cash flow and balance sheet